Conceptual Modelling for Cost-Effectiveness Analysis of Intravitreal Therapy with Ranibizumab, Aflibercept or Bevacizumab for Macular Oedema Due to Central Retinal Vein Occlusion

Macular oedema (MO) is an eye condition that can result in severe visual impairment. MO can be caused by central retinal vein occlusion (CRVO). The CRVO prevalence in the UK is estimated between 0.1% and 0.4%, with most patients (71%) being at least 65 years old. The objective of this study was to develop a conceptual model comparing bevacizumab, aflibercept and ranibizumab treatment for MO due to CRVO. The conceptual model would be used to...